QuidelOrtho Q1 2026: Navigating Challenges & Growth

QuidelOrthos Q1 2026 results show a 10% revenue drop to $620M due to a milder flu season, with flu-like illness visits down 30% and respiratory sales at $68M. Labs revenue fell 8%, but immunohematology grew 3% in North America, China, and Japan Pacific. The companys acquisition of Lex Diagnostics and launch of new products like a high-sensitivity troponin assay and VITROS four fifty platform are expected to drive growth in the second half of the year. Despite near-term challenges, QuidelOrtho tightened full-year guidance to revenue between $2B and $2.75B, adjusted EBITDA of $615M to $630M at a 23% margin, and earnings per share from $0.80 to $2.00. Support the show:Get a discount at https://solipillow.com/discount/dnn. Advertise on DNN:[email protected] This is an automated, high-level news summary based on public reporting.Report issues to [email protected]. View sources & latest updates:https://sources.thednn.ai/006537bf8918c237